Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04248855 · ClinicalTrials.gov registry record · Phase 1
Assessment of KAN-101 in Celiac Disease (ACeD)
A Phase 1 study, sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT04248855 is a Phase 1 study that has completed, run by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion. The registered enrollment target is 41 participants.
The verdict
NCT04248855, a Phase 1 study, has completed, sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2. Part B - patients will receive three doses of either KAN-101 or placebo
Interventions
- DRUG Placebo
- DRUG KAN-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2020-01-21 |
| Est. Completion | 2021-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04248855
The ClinicalTrials.gov registry entry for NCT04248855 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04248855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04248855 about?
NCT04248855 is a clinical study titled "Assessment of KAN-101 in Celiac Disease (ACeD)". A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2. Part B - patients will receive three doses of either KAN-101 or placebo
What is the current status of trial NCT04248855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2020-01-21. Estimated completion is 2021-10-08.
What interventions are being tested in trial NCT04248855?
The interventions under investigation include: Placebo (DRUG), KAN-101 (DRUG).
Who is sponsoring clinical trial NCT04248855?
This trial is sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.